Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Stanley Druckenmiller’s New Bets On Basic Materials

Page 1 of 2

The latest round of 13F filings has brought to light some interesting changes in the portfolio of hedge fund legend Stanley Druckenmiller. His fund, Duquesne Capital, now has enhanced exposure to basic materials stocks, with financial and tech stocks coming right behind. A former portfolio manager for George Soros’ Quantum Fund (now Soros Fund Management), Druckenmiller is famous for “breaking the Bank of England” in 1992, when he had massively shorted the British Pound. He founded Duquesne Capital back in 1981 and, following his departure from Quantum in 2000, has focused solely on managing his fund. In 2010, Druckenmiller closed Duquesne Capital to new investors, claiming he’d be unable to provide high returns. He continues to file 13F reports, though, and his latest moves in several basic materials stocks will be discussed below.


First a quick word on why we track hedge fund activity. In 2014, equity hedge funds returned just 1.4%. In 2013, that figure was 11.3%, and in 2012, they returned just 4.8%. These are embarrassingly low figures compared to the S&P 500 ETF (SPY)’s 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. Does this mean that hedge fund managers are dumber than a bucket of rocks when it comes to picking stocks? The answer is definitely no. Our small-cap hedge fund strategy, which identifies the best small-cap stock picks of the best hedge fund managers returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012, outperforming the market each year (it’s outperforming it so far in 2015 too). What’s the reason for this discrepancy you may ask? The reason is simple: size. Hedge funds have gotten so large, they have to allocate the majority of their money into large-cap liquid stocks that are more efficiently priced. They are like mutual funds now. Consider Ray Dalio’s Bridgewater Associates, the largest in the industry with about $165 billion in AUM. It can’t allocate too much money into a small-cap stock as merely obtaining 2% exposure would really move the price. In fact, Dalio can’t even obtain 2% exposure to many small-cap stocks, even if he essentially owned the entire company, as they’re simply too small (or rather, his fund is too big). This is where we come in. Our research has shown that it is actually hedge funds’ small-cap picks that are their best performing ones and we have consistently identified the best picks of the best managers, returning 118% since the launch of our small-cap strategy compared to less than 58% for the S&P 500 (see the details).

Stanley Druckenmiller
Stanley Druckenmiller
Duquesne Capital

Freeport-McMoRan Inc (NYSE:FCX) is one of Druckenmiller’s top new additions to his fund’s equity portfolio. According to Duquesne’s latest 13F filing, throughout the second quarter Druckenmiller built a position that comprises 3.54 million shares, which are valued at a little over $66 million as of June 30. The stock took a hammering in the first half of this year, having lost more than 60% of its value, and is currently trading at $8.78 per share. For the three months ending June 30, Freeport-McMoRan Inc (NYSE:FCX) reported revenues of $4.25 billion and a loss of $0.09 per share. Market analysts expect better results for the current quarter, eyeing revenues of $4.26 billion and earnings per share of $0.10. Ken Griffin and Mario Gabelli are also bullish on this stock, having increased their holdings during the quarter. Griffin’s stake in Freeport-McMoRan Inc (NYSE:FCX) rose by 19% to 2.72 million shares valued at $50.8 million, while Gabelli boosted his stake to 2.73 million shares worth $50.9 million, according to their respective quarterly filings.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!